Replies to post #16 on Solventum Corp (SOLV)

[DewDiligence]

SOLV’s raised 2024 guidance is as follows:

https://finance.yahoo.com/news/solventum-reports-second-quarter-2024-200500242.html

• 2024 organic sales growth of 0-1% (up from the prior range of -2% to 0%).

• 2024 non-GAAP EPS of $6.30-6.50 (up from the prior range of $6.10-6.40).

At the current share price ($60.00 as I’m typing), the midpoint of the new 2024 non-GAAP EPS guidance range represents a P/E ratio of 9.4x.

[DewDiligence]

SOLV 2Q24 Results by Business Segment

 
                          %Corp      YoY Growth     
 Segment                  Sales    Organic Sales† 
 Medical/surgical*         56%        +2% 
 Dental                    16%        -2% 
 Health-info systems       16%        +4%  
 Purification/filtration   12%        -1%

†Excludes acquisitions, divestitures, and currency.

*Includes components for other companies’ medical devices.

[DewDiligence]

SOLV reports 3Q24 results—raises 2024 guidance…

New 2024 guidance is as follows:

• Non-GAAP EPS of $6.50-6.65 (vs prior guidance of $6.30-6.50).

• Organic sales growth of 0.5-1.0% (vs prior guidance of 0-1%).

• FCF of $750-850M (vs prior guidance of $700-800M).

At the current share price (~$77 as I’m typing), the midpoint of the new 2024 non-GAAP EPS guidance range represents a P/E ratio of 11.7x.


PR:
https://investors.solventum.com/image/2024-11-07-Solventum-Reports-Third-Quarter-2024-Financial-Results-and-Raises-Full-Year-Guidance.pdf

CC slides:
https://investors.solventum.com/image/SOLV+Q3+2024+Earnings+Presentation.pdf